Amoy Diagnostics (SHE:300685) amended the registration certificate of its PD-L1 Antibody Reagent (Immunohistochemistry) product, according to a Shenzhen Stock Exchange disclosure on Thursday.
The Chinese diagnostic company changed the product's use, stating that the kit is used for in vitro qualitative detection of PD-L1 protein expression in 10% neutral buffered formalin fixed paraffin embedded gastric/gastroesophageal adenocarcinoma in patients who can be treated with sugemalimab combined with chemotherapy.